Design Therapeutics (DSGN) financial statements
Design Therapeutics reported revenue of $0 in fiscal 2025.
Net income was -$70M.
Free cash flow was -$55M.
The diluted share count rose 263% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Design Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $226,000 | — | — | — | $0 | $0 |
| Research and development | $6M | $25M | $49M | $57M | $44M | $59M |
| Selling, general and admin | $2M | $11M | $19M | $21M | $18M | $20M |
| Operating income | -$8M | -$36M | -$68M | -$78M | -$62M | -$79M |
| Income tax | — | — | — | — | $0 | $0 |
| Net income | -$8M | -$36M | -$63M | -$67M | -$50M | -$70M |
| EPS (diluted) | -$0.52 | -$0.77 | -$1.14 | -$1.19 | -$0.88 | -$1.22 |
| Diluted shares | 16M | 46M | 56M | 56M | 57M | 57M |
| Operating margin | -3685.8% | — | — | — | — | — |
| Net margin | -3663.7% | — | — | — | — | — |
Balance sheet
Fiscal years, from Design Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Cash and short-term investments | $36M | $384M | $330M | $282M | $246M | $220M |
| Total current assets | $36M | $385M | $335M | $285M | $248M | $224M |
| Property, plant and equipment | $71,000 | $2M | $2M | $2M | $1M | $981,000 |
| Total assets | $37M | $391M | $341M | $290M | $252M | $226M |
| Total current liabilities | $2M | $5M | $11M | $10M | $8M | $13M |
| Total liabilities | $2M | $8M | $14M | $12M | $10M | $14M |
| Shareholders' equity | -$11M | $382M | $327M | $278M | $242M | $213M |
| Net debt | -$2M | -$299M | -$26M | -$21M | -$23M | -$17M |
Cash flow
Fiscal years, from Design Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$9M | -$29M | -$51M | -$59M | -$43M | -$54M |
| Capital spending | $76,000 | $2M | $918,000 | $256,000 | $340,000 | $193,000 |
| Free cash flow | -$9M | -$31M | -$52M | -$59M | -$43M | -$55M |
| Stock-based compensation | $450,000 | $5M | $11M | $13M | $13M | $15M |
| Free cash flow margin | -3869.5% | — | — | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for DSGN.
Open DSGN in InvestinglyQuestions
What was Design Therapeutics's revenue in 2025?
$0 in fiscal 2025, from its 10-K filing.
How much free cash flow does Design Therapeutics generate?
-$55M in fiscal 2025 (operating cash flow minus capital spending).
From Design Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.